A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

Active:	No
Cancer Type:	Colon/Rectal Cancer Liver Cancer / Hepatoblastoma Lung Cancer	NCT ID:	NCT04943900
Trial Phases:	Phase I	Protocol IDs:	CA102-003 (primary) NCI-2021-09090
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Bristol-Myers Squibb
NCI Full Details:	http://clinicaltrials.gov/show/NCT04943900

Summary

The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels
and preliminary antitumor activity of BMS-986416 when administered alone and in combination
with Nivolumab in participants with select advanced solid tumors.

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.